Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibacterial Mouthwash for Pharyngeal Gonorrhea Prevention
NCT04966507Phase 2Completed
- Sponsor
- University of California, Los Angeles
- Start
- Feb 2022
- Primary completion
- May 2025
- Modality
- Hydrogel Systems, Transdermal Patches
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Cetylpyridinium chloride mouthwash in gonorrhea (2 arms), sponsored by University of California, Los Angeles. Primary endpoints: Mouthwash Adherence - Percent of Days Mouthwash Used at 24 weeks, Mouthwash Acceptability - Number of Participants Who Reported it Was Hard to Gargle/Rinse With Mouthwash at 24 weeks and 4 more. Started Feb 2022; status: completed.
02
Drugs
Cetylpyridinium chloride mouthwash
03
Conditions
gonorrhea
Beyond the preview
Go deeper on NCT04966507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04966507.